US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
Abstract The report covers forecast and analysis for the breast cancer liquid biopsy market on a global and regional level. The study provides historic data from 2015 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes drivers and restraints for the breast cancer liquid biopsy market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the breast cancer liquid biopsy market on a global as well as regional level. In order to give the users of this report a comprehensive view of the breast cancer liquid biopsy market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein product segment is benchmarked based on their market size, growth rate, and general attractiveness. The report provides company market share analysis in order to give a broader overview of the key players in the breast cancer liquid biopsy market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the breast cancer liquid biopsy market on the global and regional basis. The study provides a decisive view on the breast cancer liquid biopsy market by segmenting the market based on biomarkers, end users, and regions. The segments have been analyzed based on present and future trends and the market is estimated from 2017 to 2024. The biomarker segment has been segmented into Circulating Tumor Cells (CTCs), Cell-free DNA (cfDNA), Extracellular Vesicles (EVs) and Other Circulating Biomarkers. Other circulating biomarkers include cell-free protein biomarkers and circulating RNA (ctRNA and cfRNA). Cell-free DNA segment holds the maximum share of the biomarker segment. Based on end user, breast cancer liquid biopsy market has been segmented into reference laboratories, hospitals and physician laboratories, other end users. Other end users include research institutes, academic research laboratories, pathology laboratories etc. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further bifurcation into major countries including the U.S., Canada, Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes demand for pediatric medical devices based on individual segment and applications in all the regions and countries. The report also includes detailed profiles of end players such as QIAGEN N.V., Roche Diagnostics, Bio-Rad Laboratories, Myriad Genetics, Menarini Silicon Biosystems, Illumina, Cynvenio Biosystems, Inc., Genomic Health, Inc., Thermo Fisher Scientific Inc., Fluxion Biosciences, Inc., Biodesix, Inc., Guardant Health, Inc., and Isogen Life Science B.V. among others. This report segments the global Breast Cancer Liquid Biopsy Market as follows: Global Breast Cancer Liquid Biopsy Market: By Biomarker Circulating Tumor Cells (CTCs) Cell-free DNA (cfDNA) Extracellular Vesicles (EVs) Other Circulating Biomarkers (ctRNA, cfRNA and cell free proteins) Global Breast Cancer Liquid Biopsy Market: By End User Reference Laboratories Hospitals and Physician Laboratories Other End Users Global Breast Cancer Liquid Biopsy Market: By Region North America The U.S. Europe UK France Germany Asia Pacific China Japan India Latin America Brazil The Middle East and Africa
Table of Contents Request Table Of Content Click To Request Sample Chapter 1. Introduction 1.1. Report description and scope 1.2. Research scope 1.3. Research methodology 1.3.1. Market research process 1.3.2. Market research methodology Chapter 2. Executive Summary 2.1. Global Breast Cancer Liquid Biopsy Market, 2017 - 2024 (USD Million) 2.2. Global Breast Cancer Liquid Biopsy Market : Snapshot | read more...